Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...
Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December ...
Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...
TipRanks on MSN
Bank of America says market isn’t pricing in Eli Lilly’s (LLY) weight-loss drug dominance
The company’s weight-loss pill is expected to be a blockbuster.
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
Zacks Investment Research on MSN
Why this 1 momentum stock could be a great addition to your portfolio
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback